Journal: Iranian Journal of Basic Medical Sciences

Article Title: Anticancer activity of Pseudomonas aeruginosa derived peptide with iRGD in colon cancer therapy

doi: 10.22038/IJBMS.2023.68331.14913

Figure Lengend Snippet: shows how p28, either alone or in combination with iRGD and 5-FU, inhibits the development of CT26 cells in xenograft nude mice

Article Snippet: Peptide synthesis and purification ProteoGenix Inc. produced the p28 anticancer peptide (LSTAADMQGVVTDGMASGLDKDYLKPDD, 2914 Da) ( ) and the iRGD homing peptide (Ac-CRGDKGPDC-amide), a disulfide-based cyclic peptide, with >95% purity and mass balance.

Techniques:

Journal: Journal of Gastrointestinal Oncology

Article Title: Modification of erythrocytes by internalizing Arg-Gly-Asp (iRGD) in boosting the curative effect of radiotherapy for gastric carcinoma

doi: 10.21037/jgo-22-951

Figure Lengend Snippet: Schematic illustration to show the fabrication of RBC-iRGD and the therapeutic application in mice. RBC, red blood cell; DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[succinyl(polyethylene glycol)-3400]; PEG, polyethylene glycol; iRGD, internalizing arginine-glycine-aspartic acid RGD.

Article Snippet: Tumor-penetration peptide iRGD (cyclic CRGDKGPDC), Cys-iRGD (Cys-CRGDKGPDC), and Fam-CCRGDKGPDC-NH2 were custom-synthesized by ChinaPeptides Co., Ltd. (Shanghai, China).

Techniques:

Journal: Journal of Gastrointestinal Oncology

Article Title: Modification of erythrocytes by internalizing Arg-Gly-Asp (iRGD) in boosting the curative effect of radiotherapy for gastric carcinoma

doi: 10.21037/jgo-22-951

Figure Lengend Snippet: Fabrication of iRGD modified RBCs. (A) Upper layer, schematic illustration to show the fabrication of RBC-iRGD by modification of DiI (red)-stained RBCs with FAM (green)-labeled iRGD-PEG. Under layer, confocal microscopy images of single-channel red staining and green staining, and merged images of a single iRGD-modified RBC. Scale bar =1 µm. (B) Confocal microscopy images of single-channel red staining and green staining, and merged images of a iRGD-modified RBC population. Scale bar =50 µm. (C) Fluorescence-intensity evaluation of the RBC-iRGD. The figure on the left is the gate of control RBC. Flow cytometry histograms of RBCs alone (middle) and RBCs incubated with DSPE-PEG-iRGD-FAM (right). (D) Correlation analysis between the MFI and iRGD concentration (µg). Flow cytometry histograms of RBC incubated with different amounts of DSPE-PEG-iRGD-FAM. (E) Correlation analysis between the MFI and iRGD concentration (µg). Data are expressed with mean ± SD; n=3. RBC, Red blood cell; DiI, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate; DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; PEG, polyethylene glycol; iRGD, arginylglycylaspartic acid; FAM, carboxyfluorescein; SSC-A, side scatter area; FSC-A, forward scatter area; FITC-A, fluorescein isothiocyanate; MFI, mean fluorescence intensity.

Article Snippet: Tumor-penetration peptide iRGD (cyclic CRGDKGPDC), Cys-iRGD (Cys-CRGDKGPDC), and Fam-CCRGDKGPDC-NH2 were custom-synthesized by ChinaPeptides Co., Ltd. (Shanghai, China).

Techniques: Modification, Staining, Labeling, Confocal Microscopy, Fluorescence, Control, Flow Cytometry, Incubation, Concentration Assay

Journal: Journal of Gastrointestinal Oncology

Article Title: Modification of erythrocytes by internalizing Arg-Gly-Asp (iRGD) in boosting the curative effect of radiotherapy for gastric carcinoma

doi: 10.21037/jgo-22-951

Figure Lengend Snippet: Stability evaluation of the RBC-iRGD. (A) Images of RBCs with different modifications: (a) RBC; (b) RBC + iRGD; (c) RBC-iRGD. (B) Images of RBCs with different modifications after storage in RPMI 1640 medium containing 10% fetal bovine serum for 48 h: (a) RBC; (b) RBC + iRGD; (c) RBC-iRGD; (d) hemolytic RBCs. (C) FAM fluorescence evaluation of the RBC-iRGD at different time points. (D) Analysis of the percentage of FAM-iRGD using flow cytometry. (E) DiI fluorescence evaluation of the DiI stained RBCs at different time points. (F) Analysis of the percentage of DiI stained RBCs using flow cytometry. DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; PEG, polyethylene glycol; iRGD, internalizing arginine-glycine-aspartic acid RGD; FAM, carboxyfluorescein; DiI,1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate; RBC, red blood cell.

Article Snippet: Tumor-penetration peptide iRGD (cyclic CRGDKGPDC), Cys-iRGD (Cys-CRGDKGPDC), and Fam-CCRGDKGPDC-NH2 were custom-synthesized by ChinaPeptides Co., Ltd. (Shanghai, China).

Techniques: Fluorescence, Flow Cytometry, Staining

Journal: Journal of Gastrointestinal Oncology

Article Title: Modification of erythrocytes by internalizing Arg-Gly-Asp (iRGD) in boosting the curative effect of radiotherapy for gastric carcinoma

doi: 10.21037/jgo-22-951

Figure Lengend Snippet: Tumor targeting ability of iRGD modified RBCs in a systematic administration route. (A) A tumor-bearing nude mice was established by subcutaneous injection of MKN-45 cells, followed by DiR stained RBCs, RBC + iRGD, and RBC-iRGD injection for tumor tracking. Effective tumor tracking could be observed in mice treated with RBC-iRGD compared to those treated with RBCs alone or RBC + iRGD in a 60-h period. Red dashed lines, subcutaneous tumors. (B) Fluorescence intensity evaluation on incised tumors from mice injected with RBCs, RBC + iRGD, and RBC-iRGD. Apparent fluorescence accumulation could be observed tumors treated with RBC-iRGD compared to those treated with RBCs alone or RBC + iRGD. (C) A significantly decreased fluorescence signal could be observed in tumor tissues from mice injected with RBCs alone or RBC + iRGD compared to those injected with RBC-iRGD. (D) Organ fluorescence intensity evaluation for the safety purpose. Less accumulated fluorescence intensity could be observed in the liver and spleen from RBC-iRGD injected mice compared to those with RBC + iRGD. (E) Organ fluorescence intensity evaluation of safety. Less accumulation of fluorescence intensity could be observed in the liver and spleen from RBC-iRGD–injected mice compared to those treated with RBC + iRGD. (F) Fluorescence signaling distribution analysis of the tumor sections from mice injected with RBCs, RBC + iRGD and RBC-iRGD. *, P<0.05; **, P<0.01; NS, not significant. RBC, red blood cell; iRGD, internalizing arginine-glycine-aspartic acid RGD; DAPI, 4',6-diamidino-2-phenylindole.

Article Snippet: Tumor-penetration peptide iRGD (cyclic CRGDKGPDC), Cys-iRGD (Cys-CRGDKGPDC), and Fam-CCRGDKGPDC-NH2 were custom-synthesized by ChinaPeptides Co., Ltd. (Shanghai, China).

Techniques: Modification, Injection, Staining, Fluorescence

Journal: Journal of Gastrointestinal Oncology

Article Title: Modification of erythrocytes by internalizing Arg-Gly-Asp (iRGD) in boosting the curative effect of radiotherapy for gastric carcinoma

doi: 10.21037/jgo-22-951

Figure Lengend Snippet: Efficacy of RBC-iRGD in enhancement of radiotherapy in subcutaneous gastric tumor mice. (A) Schematic illustration shows the generation of the subcutaneous gastric tumor mice model, treatment with radiotherapy (5 Gy radiotherapy, 3 fractions), and RBC + iRGD and RBC-iRGD injection to monitor the tumor growth. (B) Tumor volume monitoring. A significantly decreased tumor volume could be observed in mice treated with RBC + iRGD plus radiotherapy compared to those treated with RBCs alone and control mice. Moreover, the highest tumor volume decrease was observed in mice treated with RBC-iRGD plus radiotherapy compared to those treated with radiotherapy alone and RBC + iRGD plus radiotherapy. **, P<0.01; *, P<0.05. (C) Radiotherapy or different modification on the RBCs had no effect on the bodyweight of mice. (D) HE-stained sections of major organs including the heart, liver, spleen, lungs, and kidneys collected from mice with different treatments on Day 18. Scale bar =200 µm. Radiotherapy or different modification on the RBCs did not affect the major organs. RBC, red blood cell; iRGD, internalizing arginine-glycine-aspartic acid RGD; HE, hematoxylin and eosin; IR, irradiation.

Article Snippet: Tumor-penetration peptide iRGD (cyclic CRGDKGPDC), Cys-iRGD (Cys-CRGDKGPDC), and Fam-CCRGDKGPDC-NH2 were custom-synthesized by ChinaPeptides Co., Ltd. (Shanghai, China).

Techniques: Injection, Control, Modification, Staining, Irradiation

Journal: Biomedicines

Article Title: Co-Entrapment of Sorafenib and Cisplatin Drugs and iRGD Tumour Homing Peptide by Poly[ε-caprolactone-co-(12-hydroxystearate)] Copolymer

doi: 10.3390/biomedicines10010043

Figure Lengend Snippet: Encapsulation of the iRGD peptide with DCC using 1:5 oil-in-water ratio, 1% ( w/v ) 12CL polymer concentration, and 1% ( w/v ) PVA emulsifier.

Article Snippet: Micro bicinchonionic acid (micro BCA) protein assay kit and bovine albumin (fraction V) (BSA) were bought from the Thermo Fisher Scientific (Waltham, MA, USA), iRGD peptide from GenScript USA Inc. (Piscataway, USA), and nitric acid 68–70% (HNO3) from Scharlab (Barcelona, Spain).

Techniques: Encapsulation, Polymer, Concentration Assay, Zeta Potential Analyzer